Global New Drug Reconstitution Systems Markets, 2021-2030



DUBLIN, December 8, 2021 / PRNewswire / – The “Market for New Drug Reconstitution Systems by Type of Container, Material of Construction, Physical State of Drug in Syringe and Cartridge, Physical State of Drug in Infusion Bag, Volume of Container, Regions Key Geographies: Industry Trends and Global Forecasts, the 2021-2030 report has been added to ResearchAndMarkets.com offer.

The “Novel Drug Reconstitution Systems Market” report presents an in-depth study of the current and future potential of novel drug reconstitution systems, under development to facilitate the storage and administration of lyophilized drugs, thereby maintaining the stability and the duration of the conversation. In addition, it presents an elaborate discussion of the likely opportunity for those involved in this field, over the next decade.

One of the main objectives of the report was to estimate the size of the existing market and future opportunities for new drug reconstitution systems, over the next decade. Based on various parameters, such as target consumer segments, likely adoption rates and expected prices of these products, we have provided educated estimates on how the market will develop for the period 2021-2030.

In recent years, many biologics and small molecule drugs have entered the market. Most of these biological products are not stable in the form of liquid formulations and tend to lose their effectiveness with alterations in their pharmacokinetic and pharmacodynamic properties, which makes it difficult to keep them longer. In order to obtain a longer shelf life, lyophilization has become the preferred choice for the manufacture of dry biopharmaceutical formulations.

In fact, about 30% of parenteral drugs approved by the FDA are in lyophilized form. Since 2014, the FDA has approved more than 20 new freeze-dried drug applications. Obviously, this method of producing stabilized formulations has been widely adopted and the affiliate market opportunity is estimated to be $ 3 billion.

The increased adoption of these drugs has led to an increased demand for reconstitution systems which allow proper mixing of the lyophilized drug with the diluent and delivery of the required dose. Traditional methods of reconstitution involve manual extraction and transfer of the diluent into the vials containing the lyophilized product, using a syringe and transfer needle.

Due to the large number of steps involved and the multiple containers, this method is associated with the risk of medication errors and needle stick injuries. In addition, the complexity associated with these conventional systems restricts the injection of lyophilized drugs only by healthcare personnel in the confined space of healthcare establishments.

The challenges existing in the conventional reconstitution method have prompted the pharmaceutical industry to develop advanced reconstitution devices, which allow patients and caregivers to administer drugs without the intervention of a healthcare professional. These systems contain a premeasured dose of drug and diluent, which essentially reduces the risk of dosing errors and needlestick injuries.

In addition, these advanced systems improve the portability, efficiency and optimal delivery of lyophilized drugs and have the potential to dramatically reduce the number of steps, allowing dilution and reconstitution at the time of administration. Due to their multiple advantages, various pharmaceutical companies are considering these systems for the management of the life cycle of their drugs in order to improve the delivery of health care.

In addition, it should be mentioned that over 1,800 patent applications have been filed / granted for restorative systems and associated technologies. We believe that such efforts are likely to drive the growth of this market over the next few years.

Main topics covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. PRESENTATION
3.1. Overview of chapters
3.2. Presentation of reconstitution systems
3.2.1. Key considerations in reconstituting a drug
3.3. Lyophilization of pharmaceutical products
3.3.1. Need for replenishment systems
3.3.2. Double-chamber / multi-chamber systems
3.3.3. One-step recovery systems
3.3.4. Conventional reconstitution systems
3.4. Benefits of drug reconstitution systems
3.4.1. Benefits for pharmaceutical players
3.4.2. Benefits for patients
3.5. Final remarks

4. MARKET LANDSCAPE: NEW MEDICINE RECONSTRUCTION SYSTEMS
4.1. Overview of chapters
4.2. New drug reconstitution systems: product pipeline
4.3. New drug reconstitution systems: developer landscape

5. MARKET LANDSCAPE: OTHER RECONSTITUTION SYSTEMS
5.1. Overview of chapters
5.2. One-step replenishment systems: product pipeline
5.3. One-step recovery systems: developer landscape
5.4. Conventional reconstitution devices: development pipeline
5.5. Conventional reconstruction devices: developer landscape

6. COMPANY PROFILES
6.1. Overview of chapters
6.2. Key players based in North America
6.2.1. Baxter
6.2.2. Intensive medical care
6.3. Key players based in Europe
6.3.1. B. Braun
6.3.2. Vetter Pharma
6.4. Key players based in Asia Pacific
6.4.1. Nipro
6.4.2. SCHOTT-KAISHA

7. ANALYSIS OF PACKAGING TRENDS FOR APPROVED DRUGS
7.1. Overview of chapters
7.2. Scope and methodology
7.3. List of approved drugs (2014-S1 2021)
7.4. Primary packaging containers for approved drugs
7.5. Primary packaging closures for approved drugs
7.6. Analysis of packaging trends for approved drugs: developer landscape
7.7. Final remarks

8. PATENT ANALYSIS
8.1. Overview of chapters
8.2. Scope and methodology
8.3. New drug reconstitution systems: patent analysis
8.4. New drug reconstitution systems: comparative patent analysis
8.5. New drug reconstitution systems: analysis of patent valuation
8.6. Main patents by number of citations

9. ANALYSIS OF THE COMPETITIVENESS OF THE COMPANY
9.1. Overview of chapters
9.2. Assumptions / Key Parameters
9.3. Methodology

10. ANALYSIS OF GLOBAL EVENTS
10.1. Overview of chapters
10.2. Scope and methodology
10.3. Global events related to new drug reconstitution systems

11. SWOT ANALYSIS
11.1. Overview of chapters
11.2. New drug reconstitution systems: SWOT analysis
11.2.1. Comparison of SWOT factors

12. ANALYSIS OF THE REQUEST
12.1. Overview of chapters
12.2. Scope and methodology
12.3. Global demand for dual chamber pre-filled syringes, 2021-2030
12.4. Global Demand for Dual Chamber Cartridges, 2021-2030
12.5. Global Demand for Dual / Multichamber Infusion Bags, 2021-2030
12.6. Final remarks

13. MARKET FORECASTING AND OPPORTUNITY ANALYSIS
13.1. Overview of chapters
13.2. Methodology and key assumptions
13.3. Global Dual Chamber Pre-filled Syringe Market, 2021-2030
13.4. Global Dual Chamber Cartridge Market, 2021-2030
13.5. Global Dual / Multichamber Infusion Bags Market, 2021-2030

14. FUTURE TRENDS IN PHARMACEUTICAL PACKAGING
14.1. Overview of chapters
14.2. Preference for self-medication using modern drug delivery devices
14.3. Development of innovative packaging containers
14.4. Growing demand for personalized therapies
14.5. Integration of dual chamber systems with other platforms
14.6. Increase in initiatives undertaken by industry stakeholders in developing regions
14.7. Final remarks

15. FINAL REMARKS

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

For more information on this report, visit https://www.researchandmarkets.com/r/4b9z6x

Media contact:

Research and markets
Laura Wood, senior
[email protected]

For EST office hours, call + 1-917-300-0470
For USA / CAN call toll free + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900

US Fax: 646-607-1907
Fax (outside the United States): + 353-1-481-1716

SOURCE Research and Markets

Related links

http://www.researchandmarkets.com


Previous Algernon Pharmaceuticals Completes Psychedelic Drug DMT Appoints UK Stroke Experts For Phase 2
Next Mabuza to answer who he met in Russia at the National Assembly